Network Pharmacology-Based Study on the Mechanism of Pinellia ternata in Asthma Treatment

Yanmin Lyu (✉ 995740393@qq.com)  
Shandong Academy of Medical Sciences  https://orcid.org/0000-0001-8232-679X

Xiangjing Chen  
Shandong University of Traditional Chinese Medicine

Qing Xia  
Shandong Academy of Sciences

Shanshan Zhang  
Shandong Academy of Sciences

Chengfang Yao  
Shandong Academy of Medical Sciences

Research

Keywords: asthma, hub nodes, network pharmacology, Pinellia ternata, scRNA-Seq

DOI: https://doi.org/10.21203/rs.3.rs-31449/v1

License: ☛ ☑ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

**Background:** *Pinellia ternata* (PT), a medicinal plant, has had an extensive application in the treatment of asthma in China, whereas its underlying pharmacological mechanisms remain unclear.

**Methods:** Firstly, the therapeutic effect of PT was verified by an animal experiment. Secondly, a network pharmacology method was adopted to collect activated components of PT from Traditional Chinese Medicine Systems Pharmacology Database and Analysis (TCMSP); binding targets of PT were assessed by exploiting Pharmmapper website; asthma-related targets were collected, and Target-Target interaction networks were built. Subsequently, critical nodes exhibiting high-possibility were identified as the hub nodes in the network, which employed to conduct GeneOntology (GO) comment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) signaling pathway enrichment analysis. Finally, the tissue expression profiles and single-cell RNA sequencing (scRNA-Seq) data of candidate genes were identified by Gene Expression Omnibus database (GEO) and PanglaoDB databases.

**Results:** In animal experiments, PT could alleviate the allergic response of mice by inhibiting the activation of *T-helper type 2* (TH2) cells and the secretion of IL-4 and IL-5. Subsequently, 57 achievable targets of PT on asthma were confirmed as hub nodes, included candidate genes matrix metalloproteinase-2 (*MMP2*) and nuclear receptor subfamily 3 group C member 1 (*NR3C1*). Moreover, according to transcriptome RNA sequencing data from lung tissues of allergic mice compared to normal mice, mRNA level of *MMP2* was up-regulated (*P*<0.001), and mRNA level of *NR3C1* was no significant difference (*P*=0.0749). Finally, we compared their levels of expression and distributions to those present in the single-cell level.

**Conclusions:** With network pharmacology, our study provides candidate genes that may be either used for future studies related to diagnosis/prognosis or as targets for asthma management. Besides, more attention should be paid to methods of identifying the origin of these genes and determining their expression at the single-cell level.

1. **Background**

Asthma refers to an inflammatory disorder of the airways which is induced by common aeroallergens (e.g., house dust mites, fungi, and air pollutants), and characterized by airway hyper-responsiveness, variable airflow limitation, mucous secretion, as well as chronic inflammation (1). In asthma, there exists selective expansion of T lymphocytes (particularly of TH2 cells) that secrete a cluster of cytokines such as interleukins (IL)-2, IL-4, IL-5, IL-9, IL-13, and granulocyte-macrophage colony-stimulating factor (GM-CSF), leading to mast cell differentiation and maturation, eosinophil maturation and survival, basophil recruitment, B cell differentiation and production of IgE, jointly orchestrate the allergic inflammatory cascade (2,3). On the whole, inhaled corticosteroid (ICS) or ICS combined with long-acting β2-adrenergic agonists has been the common clinical treatment to mitigate asthma. In some cases, however, corticosteroid overload raises a high risk of glucocorticoid-related adverse events and huge difficulty in
controlling the onset of asthma (4). For the asthma incidence, a single ingredient medicine cannot satisfy the existing treatment of asthma, and there is an urgent need for practical, multi-target drugs to treat asthma that can remedy the deficiencies exhibited by those that are currently available.

Traditional Chinese medicine (TCM) has been indispensable to the health of China. *Pinellia ternata*, also known as BanXia in Chinese, has been a common and potent medicinal herb in TCM practice. It has been clinically applying for suppression of the cough center to exert antitussive effects, facilitate cell division, decrease the viscosity of the whole blood, and reduce inflammation, in conjunction with other herbs (5-7). Existing studies have reported that PT attenuates ovalbumin (OVA)-induced asthma by the way of reducing the cell numbers of leucocytes, eosinophilic granulocytes and lymphocytes in lung tissues and by the way of decreasing concentration of IL-4, IL-5, IL-13 and TNF-α in bronchoalveolar lavage fluid (BALF) (8,9). However, the detailed mechanisms of their operation at molecular levels are still unknown, making it difficult any rationale in the design of more efficient and less toxic drugs for treatment. Thus, comprehensive and appropriate strategies are urgently required to gain deeper insights into how herbal formulae impact diverse biological processes in the treatment of diseases.

Network pharmacology refers to an efficient and robust method having been employed extensively for several decades to treat a range of diseases, as coupled with high-throughput group analysis, virtual computing as well as network database retrieval (10,11). Using network pharmacology in search of TCM is conducive to identifying the relationships between drug and disease, discovering active ingredients, elucidating the mechanism of action, and assessing drug safety (12). Furthermore, the recent development of scRNA-Seq technology has combined the single-cell isolation and RNA-sequencing technologies, which enabled the global transcriptome profiling on a single-cell level, offered high-resolution cell-specific gene expression for potentially unraveling of the mechanism of individual cells and greatly advanced our understanding of cellular states (13). Combination with tissue and single-cell transcription data, make it clear to identified the molecular signatures. In this study, a network pharmacological research was conducted to delve into practical components and action objectives of PT, as an attempt to explore the underlying mechanisms of action of disease treatment (Fig. 1).

2. Materials And Methods

2.1 Animal experiments

2.1.1 Mice model

All animal experiments were approved by the Institutional Animal Care and Use Committee of the Shandong Academy of Medical Science. Female C57BL/6 mice, aged 7–8 weeks, were provided by Shandong Laboratory Animal Facility (Shandong Academy of Medical Sciences, Jinan, China). All animals were housed and bred in a temperature and light-controlled environment under a 12h light-dark cycle and they were maintained under specific pathogen-free (SPF) conditions. Subsequently, mice were randomly split into three groups (the control group, the model group, and the herb group) covering four mice respectively. The model group and herb group were injected intraperitoneally (i.p.) with 50 µg OVA
(Sigma-Aldrich, MO, USA) and 2.25 mg adjuvant aluminum hydroxide (Thermo Scientific, Pittsburgh, PA, USA) in a total volume of 100 µL on day 0, 7, and 14. On day 21, the mice were intranasally (i.n.) administrated with 100 µg OVA in 50 µL. The herb group was administrated with PT (1.95 g/kg/d) (provided by affiliated hospital of Shandong University of Traditional Chinese Medicine, China) water decoction for 21 days, whereas the control mice were given the identical volume of phosphate-buffered saline (PBS). All mice were prepared for tissue harvesting.

2.1.2 Flow cytometric staining

Lungs were cut into small pieces and then incubated with 1 mg/ml collagenase D (Sigma-Aldrich, MO, USA) for 30 min and were digested into single-cell suspension. Rat-anti-mouse antibodies cover APC-CD45, PE-Cy7-CD3, PerCP-CD4, and PE-IL-5 (BD Biosciences, CA, USA). Intracellular cytokine staining was performed following the previous description (14). Flow cytometric (BD FACSVerse™, BD Biosciences, USA) data were analyzed with FlowJo software.

2.1.3 Measurement of IL-4/IL-5 in bronchoalveolar lavage fluid (BALF)

The concentration of IL-4 and IL-5 in BALF were measured using a specific mouse ELISA kit (R&D systems, Minn, USA). ELISA experiments were performed according to the manufacturer’s instructions.

2.2 Screening bioactive components of PT

The components data of PT originated from the TCMSP systems pharmacology database (http://lsp.nwu.edu.cn/tcmsp.php) (15). To achieve the bioactive components screening of PT in pharmacodynamics studies, two critical indicators have been usually taken as the screening criteria in ADME processes (e.g., absorption, distribution, metabolism, and excretion) and drug design, includes oral bioavailability (OB) and drug similarity (DL), and components were retained only if OB over 30% and DL more than 0.18 to satisfy criteria (16). In this study, based on relevant literature and the PubChem network database (https://pubchem.ncbi.nlm.nih.gov/), 11 bioactive components of PT were retained, and their corresponding information (Pubchem ID, OB and DL) was also acquired for subsequent analysis (17).

2.3 Component-related target proteins prediction

To ascertain the relevant targets of the bioactive components in PT, the PharmMapper database (http://lilab.ecust.edu.cn/pharmmapper/get.php) was adopted (18). In brief, for a given small molecule, potential candidate targets were identified using the reverse pharmaco-dynamic profiling method. Through the retrieving process, 115 assessed targets were screened out after duplicates were deleted, and make them conform to the correct Uniprot ID. Component -Target network maps were plotted by Cytoscape 3.7.2 for this data (19). Subsequently, GO enrichment and KEGG network pathway analysis were conducted on the targets acquired by using the Database for Annotation Visualization and Integrated Discovery (DAVID, https://david.nicifcrf.gov/, updated in Mar. 2017) online (20). Values of $P < 0.05$ were considered exhibiting statistical significance.
2.4 Asthma-related targets prediction

Data on the asthma-related targets were acquired from Online Mendelian Inheritance in Man database (OMIM, Updated December 21, 2019) (21,22), a comprehensive, authoritative compendium of human genes and genetic phenotypes, that is freely available and daily updated. The keyword was ‘asthma’, and 259 asthma-related targets were harvested jointly.

2.5 Protein-Protein interaction (PPI) network construction

To delve into the interaction between target proteins from a systematic and holistic perspective, PPI network mapping was conducted with String (http://string-db.org) (23). Accordingly, the “component-target-disease” network was established to express the relationships between the targets corresponding to PT and interacting protein; furthermore, such network was visually analyzed with Cytoscape 3.7.2 software. As critical parameters of network analysis, the degree of centricity (DC), betweenness centrality (BC), close to the central (CC), the network centricity (NC), and local edge connectivity topology selection (LAC) were adopted to obtain the significance of respective target. The node exhibiting a DC value higher than twice the median degree of all nodes and achieving the values of the other four indexes over the corresponding median values were defined as a hub (24). To standardly describe these genes, GO enrichment and KEGG pathway analysis were conducted by using DAVID. Values of $P < 0.05$ were considered exhibiting statistical significance.

2.6 Expression Patterns Analysis for MMP2 and NR3C1

Expression patterns in lung tissues may suggest the pathways that the target involved in asthma. GSE6858 was used to analyze expression patterns for genes acquired from the GEO database (http://www.ncbi.nlm.nih.gov/geo). In GSE6858, we compared the expression of MMP2 and NR3C1 in OVA stimulated mouse lung tissues compared to the normal group. PanglaoDB database (https://panglaodb.se/) was used to find cell types where a certain set of genes are expressed.

3. Results

3.1 PT ameliorated OVA-induced asthma

Asthma is a chronic allergic respiratory disease. Here we validated the potential anti-inflammatory and anti-asthmatic therapeutic properties of PT, using a mouse model of OVA-induced allergic asthma. Unquestionably, OVA-sensitized mice model exhibited an enhanced type 2 immune response, as the percentage of TH2 cells in lung was elevated compared with that of PBS-sensitized control mice ($^*P < 0.05$); in the case of drug treatment, the percentage of TH2 cells was noticeably reversed with PT decoction therapy ($^#P < 0.05$) (Fig. 2A). As suggested by ELISA analysis, the concentration of IL-4 and IL-5 were significantly up-regulated by OVA treatment as compared with the control group, whereas PT treatment led to the down-regulation of their levels in BALF of allergic mice (Fig. 2B).

3.2 Screening for the active component of PT
Based on the in vivo anti-asthmatic effects of PT, we further examined the therapeutic mechanism of the drug. Firstly, the 116 reported active ingredients of PT were retrieved from the TCMSP database. Then the values of OB and DL were employed to screen potential active components and 13 of the mentioned bioactive ingredients were preliminarily screened out. Besides, only 11 active ingredients with corresponding targets were screened out after the final screening from PubChem database (Table 1), most of which were sterols (beta-sitosterol, stigmasterol, cycloartenol), flavonoids (baicalein, baicalin), unsaturated fatty acid and lipid, exhibiting high oral bioavailability (rang from 30.7% to 44.72%) and high drug similarity (0.2~0.81). Moreover, these ingredients generally displayed the pharmacological activities of antibacterial, anti-inflammatory, and antioxidant.

### 3.3 Component-target network construction and enrichment analyze

Based on the data acquired above, the component-target network was established with Cytoscape 3.7.2 software (Fig. 3). In the established network, most of the components can act on multiple physiological targets, including baicalin acting on 61 targets, cycloartenol acting on 48 targets, gondoic acid acting on 26 targets, etc. Moreover, the enriched signaling pathways of these targets were analyzed by KEGG and the top 10 KEGG pathways were shown in Table 2, included PPAR signaling pathway, Thyroid hormone signaling pathway, Proteoglycans in cancer, Insulin signaling pathway, Pathways in cancer, Drug metabolism-cytochrome P450, Prolactin signaling pathway, T cell receptor signaling pathway, Metabolism of xenobiotics by cytochrome P450, and Glutathione metabolism.

### 3.4 Asthma-related targets

By searching the OMIM databases, the target data for the treatment of asthma were collected. A total of 259 targets were screened after false-positive information was checked and removed, including cytokines (e.g. TNF, IL-4, IL-5, IL-33), receptor (e.g. CCR4, IL-6R, IL-9R), chemokines (e.g. CCL2, CCL11, CCL18), and transcription factors (e.g. STAT4, STAT6, GATA3) (Table 3).

### 3.5 Hub nodes screening and PPI network construction

To elucidate the molecular mechanism underlying the effects of PT against asthma, the component-related targets and asthma-related targets were uploaded to STRING to acquire the information on PPI. 365 nodes and 3726 correlations are covered in the network. Next, according to the topology of DC, BC, CC, NC and LAC, 57 hub nodes and 808 relationships were ascertained. Among them, 47 hub genes are asthma-related targets, 8 hub genes are component-targets, MMP2 and NR3C1 are two targets which are both component-targets and highly relevant targets for asthma (Fig. 4A). We presumed those targets as the putative targets of PT for the treatment of asthma and constructed a PPI network among these 57 hub nodes (Fig. 4B).

### 3.6 Hub nodes enrichment analysis

To identify relevant pathways and functions, GO functional analysis and KEGG pathway enrichment analysis was performed for these 57 putative targets using DAVID. A total of 276
enrichment results were obtained, covering 226 Biological processes (BP), 32 Molecular functions (MF), and 18 Cellular components (CC); the enriched molecular functions of the target proteins, which are mainly associated with responses to stimulus, biological regulation, cellular process (Fig. 5A). As revealed from the KEGG enrichment analysis, the signaling pathways were notably enriched in pathways of T cell receptor signaling pathway, JAK-STAT signaling pathway, and Cytokine-cytokine receptor interaction. After extensive pathways were excluded, the top 15 relevant signaling pathways are presented in Fig. 5B. Values of $P < 0.05$ were considered exhibiting statistical significance; the lower the $P$-value, the more prominent the relevance will be.

3.7 Expression profiles and scRNA-seq data of MMP2 and NR3C1

Based on the above data, genes MMP2 and NR3C1 are both component-target and highly relevant targets for asthma. In GSE6858, the expression level of MMP2 in OVA stimulated mice was higher than that of the control group ($P < 0.001$), but between two groups, there was no significant difference in the expression level of NR3C1 (Fig. 6A). From the scRNA-seq data, MMP2 is mainly derived from stromal cells, such as fibroblasts, peritubular cells, and basal cells, while NR3C1 is mainly derived from not only stromal cells but also immune cells (e.g., T cells, B cells, dendritic cells) (Fig. 6B).

4. Discussion

The existing number of patients with bronchial asthma worldwide reaches over 300 million, and considerable patients still face difficulty in mitigating their symptoms after undergoing conventional atomization therapy, thereby developing refractory bronchial asthma (25). The mechanism of asthma pathogenesis remains unclear. Over the past years, numerous researchers have considered that airway inflammation cytokines exhibit abnormally high level on the pathogenesis of asthma and play a critical role in the process; to be specific, IL-4 is capable of stimulating the B lymphocyte to secret large specific IgE, which induces gathered eosinophils, increased airway mucosa, even airway hyperresponsiveness; IL-5 could control the differentiation, maturation, migration, and survival of eosinophils; IL-10 is capable of effectively reducing the secretion activity of mast cells and TH2 cells and exerts a definite effect on the reduction of airway inflammation; both IL-13 and IL-17 are critical pro-inflammatory cytokines in the body, thereby facilitating the synthesis of IgE, elevating the level of vascular adhesion molecules and increasing the degree of eosinophil infiltration in the airway (2,26). All of these genes are included in the asthma-related targets (Table 3). Besides, obesity, metabolic disease, and age can also act as risk factors exacerbating asthma (27). As impacted by heterogeneous in terms of severity, individual difference, and treatment responsiveness, the diverseness of this disease results in multiple therapeutic strategies. Several studies have reported that PT possesses anti-inflammatory and anti-allergic effects both in asthma and in COPD (8,28). However, the physiological and pharmacological actions of PT on asthma and its biological function have not been effectively studied. The incorporation of traditional Chinese medicine into clinical therapy via network pharmacology can provide insights into the possible mechanism and enhance the specificity and effectiveness of the treatment scheme (10).
In our study, flow cytometry analysis revealed that in allergic mice model, PT could attenuate allergic immune response by inhibiting the activation of TH2 cells and the concentration of IL-4 and IL-5. These data suggest that PT have a therapeutic effect on asthma. Then, active ingredients were screened in PT, primarily flavonoids, sterol, glycosides, and unsaturated fatty acid and proteins considered potential targets of ingredients employing to treat asthma were predicted. As further revealed from the KEGG enrichment analysis, the component-related targets primarily participated in PPAR signaling pathway (a nuclear hormone receptor is critical to regulating lipid metabolism, lipid oxidation, and cell proliferation, facilitate adipocyte differentiation and enhance glucose uptake), thyroid hormone signaling pathway (vital regulators of growth, development, and metabolism), proteoglycans in cancer (critical macromolecules contributing to the biology of cancer, covering proliferation, adhesion, angiogenesis, and metastasis) and several metabolic pathways (e.g., cytochrome P450, prolactin signaling pathway, and glutathione metabolism).

In the PPI network of component-targets and asthma-related targets, hub nodes were screened, and the GO enrichment analysis and the KEGG pathway enrichment analysis were performed to clarify the multiple mechanisms systematically. Based on the GO terms, the activity of hub nodes was associated with numerous biologic processes (e.g., inflammatory response, chemotaxis and immune response), variety molecular functions (e.g., cytokine activity, growth factor activity, and protein tyrosine kinase activity) and diversified cellular components (e.g., extracellular space, extracellular region, and external side of plasma membrane). Thus, the results demonstrated that PT primarily exerted various therapeutic effects on asthma by participating in these processes and functions. In the cytokine-cytokine receptor interaction pathway, 17 of 57 hub nodes were included and critical to the department of asthma; among them, TSLP, IL-2, and IL-4 were strong inducers capable of directly activating TH2 cells and ILC2s even on the macrophage, respectively (25,29-31). IL-5 could activate and recruit eosinophils, IL-13 activates goblet cells, CCL2, CCL11 and CXCL16 recruit and chemotactic immune cell, all of which led to an allergic reaction. Furthermore, the JAK-STAT signaling pathway is one of a handful of pleiotropic cascades and plays essential roles during development and cellular processes (e.g., segmentation, proliferation, and organogenesis) (32). JAK kinases could selectively phosphorylate STATs, leading to their activation. To be specific, STAT6 acted as one of the primary members in JAK-STAT pathway, capable of specifically inducing TH2 cell differentiation and promoting the differentiation of TH2 cytokines (e.g., IL-4, IL-5 and IL-13), and facilitating the dominant expression of TH2 cells in asthma (33). T cells are critical to defending the body against pathogens. Different T cell lineages express different types of T cell antigen receptors (TCRs). Stimulation of T cells with antigens or cytokines requires the translation of antigen binding to the TCR, so T-cell proliferation, cytokine production, cell motility, and proliferation are to be induced (34).

Undoubtedly, matrix metalloproteinase-2 (MMP2) and nuclear receptor subfamily 3 group C member 1(NR3C1) are two hub nodes, members of both component-targets and asthma-targets, making them crucial accounting for PT in asthma treatment. MMPs are a family of enzymes characterized by a common zinc ion at their active site. In general, MMPs are thought to be involved in the normal maintenance of the extracellular matrix and inflammation and cell-cell signaling (35). Studies reported
that the main function of MMP2 protease is to degrade extracellular matrix proteins and participate in airway remodeling in asthma (36). Using MMP-2-cleavable activatable cell-penetrating peptides (ACPPs) with the cleavage sequence PLGC(Me)AG, show that MMP-2 is up-regulated in the lungs of allergen OVA-challenged mice (37), this result is consistent with findings in Fig. 6A. Furthermore, the highest MMP-2 activity was detected in the areas of inflammation surrounding airways, a major site of fibroblasts, epithelial cells, basal cells, this finding is also consistent with data in scRNA-Seq. Besides, NR3C1 is vital for regulating inflammatory responses and capable of impacting the number of the glucocorticoid receptor (GR) and the affinity between the glucocorticoid receptor and glucocorticoid (38). The stress hormone cortisol binds to glucocorticoid receptors produced by NR3C1, which triggers transcriptional processes resulting in reduced inflammation (39). Reduced expression of NR3C1 may lead to fewer receptors for cortisol to bind to and carry out its functions and lead to glucocorticoid resistance, which gives rise to the inflammatory response that can become chronically over-activated and increase susceptibility to inflammatory disease over time (40). Actually, many individuals with asthma rely on corticosteroid medications to control asthma symptoms (41). While in animal experiments, NR3C1 is apparently revealed a large gap in lung tissues of normal mice, ubiquitously expressed lower in most allergic mice lung tissues (Fig. 6B). scRNA-Seq revealed that NR3C1 is mainly derived from germ cells, stromal cells (e.g., basal cells, fibroblasts, epithelial cells) and immune cells (e.g., T cells, B cells, dendritic cells), these data indicate that the expression level of NR3C1 is related to gender, genetic background, and immune microenvironment individuals. Thus, identifying factors affecting NR3C1 expression is important for improving health, particularly for those with asthma.

5. Conclusions

TCM has been commonly used to treat various diseases and exhibits favorable efficacy, whereas the molecular mechanism of TCM has not been elucidated. In the present study, the network pharmacology method was used to study the scientific basis of PT in the treatment of asthma. 57 hub nodes were screened and signaling pathways associated with asthma were enriched, these data lay a scientific basis for the clinical treatment of asthma and also provide insights into the development and utilization of drugs. The recent development of scRNA-Seq technology has combined the single-cell isolation and RNA-sequencing technologies which enabled the global transcriptome profiling on a single-cell level, greatly advanced our understanding of cellular states, and also provides an accurate direction for TCM treatment of diseases. Furthermore, systematic and rigorous experiments are required to verify our findings.

Abbreviations

TH2 cells, T helper type 2 cells; IL-2, interleukin-2; GM-CSF, granulocyte macrophage colony–stimulating factor; ICS, inhaled corticosteroid; TCM, Traditional Chinese medicine; PT, *Pinellia ternata*; OB, oral bioavailability; DL, drug similarity; GO, GeneOntology; KEGG, Kyoto Encyclopedia of Genes and Genomes; OMIM, Online Mendelian Inheritance in Man database; DC, degree of centricity; BC, betweenness centrality; CC, close to the central; NC, the network centrality; LAC, local edge connectivity topology
selection; SPF, specific pathogen-free; OVA, ovalbumin; BALF, bronchoalveolar lavage fluid; BP, biological processes; MF, molecular functions; CC, cellular components; MMP2, matrix metalloproteinase-2; NR3C1, nuclear receptor subfamily 3 group C member 1; ACPPs, activatable cell-penetrating peptides; GR, glucocorticoid receptor;

**Declarations**

**Acknowledgment**

none

**Funding**

This work was supported by Natural Science Foundation of Shandong Province [ZR2019PH114]

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request

**Author contributions**

YML carried out the major experiments and drafted the manuscript. XJC, QX, and SSZ supported in the study design, reviewed the protocol, and participated to interpret the primary outcome. CFY led the overall project and designed experiments.

**Ethics approval and consent to participate**

Not applicable

**Consent for publication**

Not applicable.

**Competing interests**

The authors have no competing interests.

**Reference**

1. LB M, EB B, JB M, et al. Environmental exposures and mechanisms in allergy and asthma development. The Journal of clinical investigation 2019;129:1504-15.

2. BN L, H H, JV F. The Cytokines of Asthma. Immunity 2019;50:975-91.
3. ME K, FE L, GB L. Understanding Asthma Phenotypes, Endotypes, and Mechanisms of Disease. Clinical reviews in allergy & immunology 2019;56:219-33.

4. POB, LM F, ID P, et al. Asthma progression and mortality: the role of inhaled corticosteroids. The European respiratory journal 2019;54:undefined.

5. SY, Y Y, JW, et al. Banxia Xiexin decoction, a traditional Chinese medicine, alleviates colon cancer in nude mice. Annals of translational medicine 2019;7:375.

6. HL, J Q, NH, et al. Banxia Xiexin Decoction Is Effective to Prevent and Control Irinotecan-Induced Delayed Diarrhea in Recurrent Small Cell Lung Cancer. Integrative cancer therapies 2018;17:1109-14.

7. CS T, YC L, CH N, et al. Anti-hypertensive and vasodilatory effects of amended Banxia Baizhu Tianma Tang. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018;97:985-94.

8. MY L, IS S, WY J, et al. Pinellia ternata Breitenbach attenuates ovalbumin-induced allergic airway inflammation and mucus secretion in a murine model of asthma. Immunopharmacology and immunotoxicology 2013;35:410-8.

9. IS O, SH K, BK K, et al. Pinellia ternata, Citrus reticulata, and their combinational prescription inhibit eosinophil infiltration and airway hyperresponsiveness by suppressing CCR3+ and Th2 cytokines production in the ovalbumin-induced asthma model. Mediators of inflammation 2009;2009:413270.

10. BB, KA, PD, et al. Network-based Approaches in Pharmacology. Molecular informatics 2017;36:undefined.

11. RZ, ZX, HB, et al. Network Pharmacology Databases for Traditional Chinese Medicine: Review and Assessment. Frontiers in pharmacology 2019;10:123.

12. WYL, CY L, YS K, et al. The Methodological Trends of Traditional Herbal Medicine Employing Network Pharmacology. Biomolecules 2019;9:undefined.

13. ZW, HD, QZ. Identifying cell types to interpret scRNA-seq data: how, why and more possibilities. Briefings in functional genomics 2020.

14. ZX, YG, LW, et al. Recovery Profiles of T-Cell Subsets Following Low-Dose Total Body Irradiation and Improvement With Cinnamon. International journal of radiation oncology, biology, physics 2015;93:1118-26.

15. JR, PL, JW, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. Journal of cheminformatics 2014;6:13.

16. YV, JH, XX. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. The AAPS journal 2012;14:714-27.

17. YW, SH B, TC, et al. PubChem BioAssay: 2017 update. Nucleic acids research 2017;45:D955-D63.

18. XW, Y S, SW, et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic acids research 2017;45:W356-W60.

19. PS, AM, OO, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome research2003. p. 2498-504.
20. W Hd, BT S, RA L. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 2009;4:44-57.

21. JS A, CA B, F S, et al. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic acids research 2015;43:D789-98.

22. JS A, A H. Searching Online Mendelian Inheritance in Man (OMIM): A Knowledgebase of Human Genes and Genetic Phenotypes. Current protocols in bioinformatics 2017;58:1.2.1-.2.12.

23. D S, JH M, H C, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic acids research 2017;45:D362-D8.

24. Y W, Z L, C L, et al. Drug target prediction based on the herbs components: the study on the multitargets pharmacological mechanism of qishenkeli acting on the coronary heart disease. Evidence-based complementary and alternative medicine : eCAM 2012;2012:698531.

25. Ray A, Raundhal M, Oriss TB, et al. Current concepts of severe asthma. J Clin Invest 2016;126:2394-403.

26. ST H. Innate and adaptive immune responses in asthma. Nature medicine 2012;18:673-83.

27. Kankaanranta H, Kauppi P, Tuomisto LE, et al. Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms. Mediators Inflamm 2016;2016:3690628.

28. W D, J S, D Y, et al. Pinellia ternata Attenuates Mucus Secretion and Airway Inflammation after Inhaled Corticosteroid Withdrawal in COPD Rats. The American journal of Chinese medicine 2016;44:1027-41.

29. Kanagalingam T, Solomon L, Vijeyakumaran M, et al. IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation? Immun Inflamm Dis 2019;7:112-24.

30. Zhu J. T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production. Cytokine 2015;75:14-24.

31. Liu S, Verma M, Michalec L, et al. Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma: The role of thymic stromal lymphopoietin. J Allergy Clin Immunol 2018;141:257-68 e6.

32. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci 2018;27:1984-2009.

33. Stokes K, LaMarche NM, Islam N, et al. Cutting edge: STAT6 signaling in eosinophils is necessary for development of allergic airway inflammation. J Immunol 2015;194:2477-81.

34. Kuwabara T, Matsui Y, Ishikawa F, et al. Regulation of T-Cell Signaling by Post-Translational Modifications in Autoimmune Disease. Int J Mol Sci 2018;19.

35. AY H, F K. The Role of Matrix Metalloproteinases in Development, Repair, and Destruction of the Lungs. Progress in molecular biology and translational science 2017;148:1-29.

36. Y K, T K, CN DA-G, et al. Role of Matrix Metalloproteinase-2 in Eosinophil-Mediated Airway Remodeling. Frontiers in immunology 2018;9:2163.
37. CN F, EN S, M W, et al. Detection and monitoring of localized matrix metalloproteinase upregulation in a murine model of asthma. American journal of physiology Lung cellular and molecular physiology 2014;306:L764-74.

38. M P, T P, A F, et al. The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients. Inflammation 2015;38:1479-92.

39. Panek M, Pietras T, Antczak A, et al. The role of functional single nucleotide polymorphisms of the human glucocorticoid receptor gene NR3C1 in Polish patients with bronchial asthma. Mol Biol Rep 2012;39:4749-57.

40. PJ B, IM A. Glucocorticoid resistance in inflammatory diseases. Lancet (London, England) 2009;373:1905-17.

41. R B, J H, G B, et al. Inhaled Corticosteroid Therapy in Adult Asthma. Time for a New Therapeutic Dose Terminology. American journal of respiratory and critical care medicine 2019;199:1471-7.

Tables

Table 1 Active components and ADME parameters of *Pinellia Ternate*

| MOL ID   | Molecule Name                          | OB  | DL   |
|----------|----------------------------------------|-----|------|
| MOL001755 | 24-Ethylcholest-4-en-3-one              | 36.08 | 0.76 |
| MOL002670 | Cavidine                               | 35.64 | 0.81 |
| MOL002714 | Baicalein                              | 33.52 | 0.21 |
| MOL002776 | Baicalin                               | 40.12 | 0.75 |
| MOL000358 | beta-sitosterol                        | 36.91 | 0.75 |
| MOL000449 | Stigmasterol                           | 43.83 | 0.76 |
| MOL005030 | Gondoic acid                           | 30.7  | 0.2  |
| MOL000519 | Coniferin                              | 31.11 | 0.32 |
| MOL006936 | 10,13-eicosadienoic                   | 39.99 | 0.2  |
| MOL003578 | Cycloartenol                           | 38.69 | 0.78 |
| MOL006967 | beta-D-Ribofuranoside, xanthine-9      | 44.72 | 0.21 |

ADME, (absorption, distribution, metabolism, and excretion); OB, oral bioavailability; DL, drug similarity.

Table 2 The Top 10 KEGG pathways of component-related targets.
| Term                                      | Count | P Value    | Gene                                                                 |
|-------------------------------------------|-------|------------|----------------------------------------------------------------------|
| PPAR signaling pathway                    | 9     | 2.79E-06   | FABP6, FABP7, PCK1, PDPK1, PPARA, PPARD, PPARG, RXRA, RXRB           |
| Thyroid hormone signaling pathway         | 10    | 2.21E-05   | ESR1, GSK3B, MDM2, PDPK1, RAF1, RXRA, RXRB, SRC, THRA, THRB         |
| Proteoglycans in cancer                   | 12    | 7.21E-05   | ESR1, FGFR1, GRB2, KDR, MAPK14, MDM2, MET, MMP2, PDPK1, PPP1CC, RAF1, SRC |
| Insulin signaling pathway                 | 10    | 9.34E-05   | CALM1, EIF4E, GRB2, GSK3B, INSR, PCK1, PDPK1, PPP1CC, PYGL, RAF1    |
| Pathways in cancer                        | 16    | 2.23E-04   | DAPK1, FGFR1, GRB2, GSK3B, GSTP1, MDM2, MET, MMP2, PPARD, PPARG, RAF1, RARA, RARB, RXRA, RXRB, XIAP |
| Drug metabolism - cytochrome P450          | 7     | 2.90E-04   | ADH5, GSTA1, GSTA3, GSTM1, GSTM2, GSTP1, GSTT2                       |
| Prolactin signaling pathway               | 7     | 3.67E-04   | ESR1, ESR2, GRB2, GSK3B, MAPK14, RAF1, SRC                          |
| T cell receptor signaling pathway         | 8     | 3.79E-04   | GRB2, GSK3B, IL2, ITK, LCK, MAPK14, PDPK1, RAF1                     |
| Metabolism of xenobiotics by cytochrome P450 | 7     | 4.59E-04   | ADH5, GSTA1, GSTA3, GSTM1, GSTM2, GSTP1, GSTT2                      |
| Glutathione metabolism                    | 6     | 5.83E-04   | GSTA1, GSTA3, GSTM1, GSTM2, GSTP1, GSTT2                            |

KEGG, Kyoto Encyclopedia of Genes and Genomes
| Table 3 | Related targets of asthma |
|--------|---------------------------|
|        |                           |
| Gene 1 | Gene 2 | Gene 3 | Gene 4 | Gene 5 | Gene 6 | Gene 7 | Gene 8 | Gene 9 | Gene 10 | Gene 11 | Gene 12 | Gene 13 | Gene 14 |
|-------|-------|-------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| PDE4D | HLA-G | IL6R  | TNFRSF4| TPSB2  | CD274  | ADORA2| PTGIR  |
| HNMT  | ADAM33| TYR03 | SERPINB| VEGFA  | IL25   | TACR2  | CFB    |
| VDR   | PLA2G7| MMP12 | SERPINB| SUV39H1| PDCD1LG2| CYP26A1| TACR3  |
| MMP2  | IRAK3 | GABRA2| FKBPP5 | HRH1   | TPSD1  | TRPV1  | CTSK   |
| BTK   | C5    | GAD2  | CPN1   | FABP4  | IL31   | TOP2A  | CTSB   |
| NR1I2 | CCL11 | HAVCR1| ADCY9  | STAT4  | NKAIN2 | ROS1   | CTSS   |
| ADH5  | LTC4S | MUC7  | CCL18  | MUC5B  | JAML   | SELE   | CTB    |
| VDR   | NGS   | C5AR1 | MARCKS | IL11R  | ORMDL1 | CXCR2  | AOC3   |
| NR3C1 | FLG   | GABRB2| C3AR1  | CX3CR1 | ORMDL2 | PDE3A  | CCR4   |
| NPSR1 | IL12B | TPT1  | RASGRP| IL12RB1| TAS2R31| SELENOP| NOCT   |
| IL13  | ORMDL3| CCR5  | SETDB2 | CCR6   | ACTG2  | SELL   | CNOT6  |
| TNF   | SCGB1A| PTEN  | POSTN  | JAG1   | CLC    | ADRB2  | TLR9   |
| IL4R  | TBX21 | DAP3  | DENND1B| SATB1  | MIF    | MCL1   | UTS2R  |
| IL9   | HLA-DRB1| TLR4 | CRHR1  | JAG2   | IL17F  | F2     | TSLP   |
| ALOX5 | HLA-DRB1| GAD1 | CD74   | CXADR  | MYL3   | ADRB3  | CSF2RB |
| PTGDR | HLA-DRB1| TNIP1| FCAR   | H3C1   | ABCA1  | PDE4A  | PTGER4 |
| TBX2R | SCGB3A2| C3   | ITGB6  | CST7   | CAV3   | HR     | TLR7   |
| PTGDR2| MMP9  | FCER1A| IL11   | ALOX15B| HPS1   | ESERRA | NOS2   |
| CYSLTR1| IL13RA1| PRKCA| ALOX15 | FFAR2  | ALG9   | ITGA5  | NANO5  |
| IL4   | CHI3L1| IRF4  | LTA    | KCNMB1 | CDHR3  | CCL2   | SERPINE1|
| IL5   | CMA1  | TNFSF10| TRAF5  | SIGLEC5| IL5RA  | PRSS1  | CBR1   |
| IL13RA2| MS4A2 | SOCS3 | CFTR   | CBX5   | ANGPT2 | PLA2G1B| ITGA4  |
| ALOX5AP| IL9R  | TNFSF14| MUC5AC | ICOS   | CHRNA7 | HAL    | KCNN1A |
| CYSLTR2 | CHIA | SART1 | SNCA | FCGR2B | ANGPT1 | SYK | MAP3K9 |
|---------|------|-------|------|--------|--------|-----|--------|
| SELP    | GATA3| BPIFA1| NFKB1| CD209  | MC4R   | TACR1| ADRA2C |
| PTA FR  | RUNX3| SPRED1| NFKB2| TAS2R14| IL17A | MICU1| BD KRB2 |
| PTGER3  | CCL24| GLCCI1| PTGER2| TAS2R10| IL17RA| SCN9A| OPN4   |
| CCR3    | SPINK5| USP38| PTPN6| PDE11A| CHRM4 | SCN10A| PDE5A |
| LTB4R2  | NOD1 | IL10  | SPRR2A| HDAC3 | CHRM2 | TBXAS1| CSF2   |
| IL33    | PHF11| LGALS3| SPRR2B| KCNMB2| CHRM3 | LTB4R | ADRB1  |
| PLA2G4A | DPP10| NFKBIA| TNC  | LY96  | CAMP  | ACKR3 | CHRM5  |
| STAT6   | HSD11B2| SERPINB2| TPSAB1| CXCL16| CHAMP1| ADORA1| MME    |
| ATP2A2  | ACE  | TYK2  |      |        |        |      |        |

The targets are shown by their gene names

**Figures**
**Figure 1**

The schematic illustration of network pharmacology analysis for exhibiting pharmacological pathways of PT against asthma
Figure 1

The schematic illustration of network pharmacology analysis for exhibiting pharmacological pathways of PT against asthma.
Figure 2

Alleviated allergic reactions in the treatment of PT. (A) The percentages of TH2 cells (CD45+ CD3+CD4+ IL5+) in lymphocytes by FACS; (B) The concentration of IL-4 and IL-5 in BALF. Data shown were normalized to the reference gene GAPDH. Values are expressed as mean ± SEM. * P value < 0.05 compared to control group; # P value <0.05 compared to model group.
Figure 2

Alleviated allergic reactions in the treatment of PT. (A) The percentages of TH2 cells (CD45+ CD3+CD4+ IL5+) in lymphocytes by FACS; (B) The concentration of IL-4 and IL-5 in BALF. Data shown were normalized to the reference gene GAPDH. Values are expressed as mean ± SEM. * P value < 0.05 compared to control group; # P value <0.05 compared to model group.
Figure 3

Component-Target network (C-T Network). The network of 11 active ingredients of PT and 115 putative targets was generated with Cytoscape version 3.7.2. All protein targets are represented by their gene symbol.
Figure 3

Component-Target network (C-T Network). The network of 11 active ingredients of PT and 115 putative targets was generated with Cytoscape version 3.7.2. All protein targets are represented by their gene symbol.
Figure 4

Network of drug and disease targets. (A) The targets of asthma and compounds; (B) Network of hub nodes. The property of the purple nodes are asthma-related targets; the property of the pink nodes are component-related targets, and the property of the green nodes are common targets of asthma and components.
Figure 4

Network of drug and disease targets. (A) The targets of asthma and compounds; (B) Network of hub nodes. The property of the purple nodes are asthma-related targets; the property of the pink nodes are component-related targets, and the property of the green nodes are common targets of asthma and components.
Figure 5

Enrichment analysis of the hub genes for Pinellia Ternatea in the treatment of asthma. (A) The GO enrichment analysis of hub nodes; (B) The top15 KEGG pathway enrichment analysis of hub nodes.
Figure 5

Enrichment analysis of the hub genes for Pinellia Ternatea in the treatment of asthma. (A) The GO enrichment analysis of hub nodes; (B) The top15 KEGG pathway enrichment analysis of hub nodes.
Figure 6

Gene expression levels of MMP2 and NR3C1 in tissue and single cells. (A) Gene expression levels of lung tissue in GSE6858; (B) Expression of genes in multiple cell types of human from scRNA-seq datasets, include non-adult and non-primary samples (embryo, fetal, post-natal development, cell lines)
Figure 6

Gene expression levels of MMP2 and NR3C1 in tissue and single cells. (A) Gene expression levels of lung tissue in GSE6858; (B) Expression of genes in multiple cell types of human from scRNA-seq datasets, include non-adult and non-primary samples (embryo, fetal, post-natal development, cell lines)